Literature DB >> 3619169

Intravenous use of glycopyrrolate in acute respiratory distress due to bronchospastic pulmonary disease.

C M Slovis, G M Daniels, D R Wharton.   

Abstract

A patient with acute respiratory distress secondary to emphysema and reactive airway disease had inadequate tidal volumes with and without endotracheal intubation. Because of the patient's failure to respond to maximal standard bronchodilator therapy and the physical inability to ventilate the patient by manual positive pressure, he received IV glycopyrrolate (0.2 mg) approximately 50 minutes after admission to the ED. The patient's condition immediately improved, as evidenced by the ability to manually ventilate the patient; he developed increased tidal volumes; and he began responding to inhalation therapy. This is the first reported case of IV glycopyrrolate administration for chronic obstructive pulmonary disease or asthma in the literature and demonstrates an instance in which inhalation therapy was ineffective due to low tidal volumes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3619169     DOI: 10.1016/s0196-0644(87)80530-9

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  2 in total

1.  Glycopyrronium bromide blocks differentially responses mediated by muscarinic receptor subtypes.

Authors:  H Fuder; M Meincke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

Review 2.  Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.

Authors:  Santosh Dhungana; Gerard J Criner
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-08-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.